Rapport Therapeutics
Gavin Daigle is an accomplished professional in the biotechnology and pharmaceutical industries, currently serving as Senior Director and Head of Translational Medicine at Rapport Therapeutics since July 2024. Previously, Daigle held the position of Director of Neurobiology and Translational Sciences at Sensorium Therapeutics, and served as Associate Director of Biology and Translational Sciences at Remix Therapeutics, where efforts focused on advancing small molecule therapeutics for various diseases. At Neuron23 Inc., Daigle worked as Associate Director and Senior Scientist, leading program initiatives for therapies targeting genetically-defined neurological conditions. Earlier experience includes a Senior Scientist role at AbbVie, specializing in Tau biological mechanisms in Alzheimer's disease. Daigle's education includes certificates from Harvard Business School Online and MIT Sloan School of Management, emphasizing leadership and influence.
This person is not in any teams
This person is not in any offices
Rapport Therapeutics
1 followers
Rapport Therapeutics operates as a clinical-stage biotechnology company, that discovers and develops precision medicines for neurological disorders. Rapport Therapeutics describes relationships that are defined by understanding, communication, teamwork, and trust.